RUA Life Sciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of RUA Life Sciences generated cash of -$1,328,000, which is less than the previous year. Cash used in financing activities reached the amount of $3,888,000 last year. Net change in cash is therefore $2,447,000.
Cash Flow
| 2010 | -2.05M | 34K | 0 |
|---|---|---|---|
| 2011 | -1.47M | -45.88K | 0 |
| 2012 | 48.90K | -238.52K | 0 |
| 2016 | 84.70K | -116.64K | 0 |
| 2018 | 347K | -16K | 0 |
| 2020 | -431K | -5K | 0 |
| 2021 | -1.42M | -943K | 6.68M |
| 2023 | -1.17M | -449K | 132K |
| 2024 | -1.32M | -85K | 3.88M |
RUA.L Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.48M | 2.96M | 1.97M | 2.41M | 90.98K | 242.31K | 1.38M | 1.79M | 4.17M |
Operating activities | |||||||||
Net income | -1.44M | -2.00M | -1.45M | -816K | -34K | -419.35K | 35.92K | -2.41M | -1.92M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 364K | 358K | 272K | 194K | 153K | 165.93K | 187.62K | 365.09K | 400K |
Stock-based compensation expense | -35K | 102K | 128K | 91K | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | -35K | 102K | 128K | 91K | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -362K | 860K | -467K | -20K | 176K | 342.98K | 0 | 0 | 0 |
Inventories | -31K | 43K | 7K | 0 | 0 | 0 | 18.96K | 6.98K | 0 |
Accounts payable | 104K | -203K | 231K | 120K | -5.28K | -72.37K | 0 | 0 | 0 |
Cash generated by operating activities | -1.32M | -1.17M | -1.42M | -431K | 347K | 84.70K | 48.90K | -1.47M | -2.05M |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -55K | -449K | -620K | -5K | -16.60K | -111.54K | -450.09K | -127.68K | -102K |
Acquisitions Net | 0 | 0 | -323K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -85K | -449K | -943K | -5K | -16K | -116.64K | -238.52K | -45.88K | 34K |
Financing activities | |||||||||
Common Stock Issued | 3.97M | 0 | 6.46M | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -86K | 132K | -222K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 3.88M | 132K | 6.68M | 0 | 0 | 0 | 0 | 0 | 0 |
Net Change In Cash | 2.44M | -1.47M | 4.31M | -436K | 331.01K | -24.30K | -185.50K | -935.90K | -1.29M |
Cash at end of period | 3.93M | 1.48M | 6.29M | 1.97M | 422K | 218.01K | 1.19M | 859.36K | 2.88M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |